Thalidomide increases in vitro sensitivity of childhood acute lymphoblastic leukemia cells to prednisolone and cytarabine

Archivum Immunologiae et Therapiae Experimentalis

Volumn 54, Issue 5, 2006, Pages 341-345

  Czyżewski, Krzysztof ^a   Zaborowska, Agnieszka ^a   Styczyński, Jan ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b Department of Pediatric Hematology and Oncology ^*  (Poland)

Author keywords

Acute lymphoblastic leukemia; Children; Cytarabine; Drug resistance; Prednisolone; Thalidomide

Indexed keywords

CYTARABINE; PREDNISOLONE; THALIDOMIDE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MALE;

EID: 33750325569     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-006-0036-9     Document Type: Article

References (15)

1. Dalle J. H., Leblond P., Decouvelaere A., Yakoub-Agha I., Preudhomme C., Nelken B. and Mazingue F. (2003): Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow transplantation for T-ALL. Leukemia, 17, 2056-2057.
2. El-Obeid A., Sunnuqrut N., Hussain A., Al-Hussein K., Gutierrez M. I. and Bhatia K. (2004): Immature B cell malignancies synthesize VEGF, VEGFR-1 (Flt-1) and VEGFR-2 (KDR). Leuk. Res., 28, 133-137.
3. Hideshima T., Chauhan D., Shima Y., Raje N., Davies F. E., Tai Y. T., Treon S. P., Lin B., Schlossman R. L., Richardson P., Muller G., Stirling D. I. and Anderson K. C. (2000): Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
4. Johnston R. E. and Abdalla S. H. (2002): Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leuk. Lymphoma, 43, 351-354.
5. Matthews S. J. and McCoy C. (2003): Thalidomide: a review of approved and investigational uses. Clin. Ther., 25, 342-395.
6. Merup M., Kutti J., Birgergard G., Mauritzson N., Bjorkholm M., Markevarn B., Maim C., Westin J., Palmblad J. and Swedish National Study Group on Chronic Myeloproliferative Disorders (2002): Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med. Oncol., 19, 79-86.
7. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Richardson P. G., Hideshima T., Munshi N. C., Treon S. P. and Anderson K. C. (2002): Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525-4530.
8. Mitsiades N., Mitsiades C. S., Poulaki V., Chauhan D., Richardson P. G., Hideshima T., Munshi N., Treon S. P. and Anderson K. C. (2002): Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood, 99, 4079-4086.
9. Miyachi H., Azuma A., Hioki E., Iwasaki S., Kobayashi Y. and Hashimoto Y. (1996): Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem. Biophys. Res. Commun., 224, 426-430.
10. Munshi N. C., Hideshima T., Carrasco D., Shammas M., Auclair D., Davies F., Mitsiades N., Mitsiades C., Kim R. S., Li C., Rajkumar S. V., Fonseca R., Bergsagel L., Chauhan D. and Anderson K. C. (2004): Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood, 103, 1799-1806.
11. Steins M. B., Padro T., Bieker R., Ruiz S., Kropff M., Kienast J., Kessler T., Buechner T., Berdel W. E. and Mesters R. M. (2002): Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood, 99, 834-839.
12. Styczynski J., Wysocki M., Balwierz W. and Kowalczyk J. R. (2002): Dexrazoxane has no impact on sensitivity of childhood leukemic blasts to daunorubicin. Leukemia, 16, 820-825.
13. Strupp C., Germing U., Aivado M., Misgeld E., Haas R. and Gattermann N. (2002): Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia, 16, 1-6.
14. Richardson P. G., Schlossman R. L., Weller E., Hideshima T., Mitsiades C., Davies F., LeBlanc R., Catley L. P., Doss D., Kelly K., McKenney M., Mechlowicz J., Freeman A., Deocampo R., Rich R., Ryoo J. J., Chauhan D., Balinski K., Zeldis J. and Anderson K. C. (2002): Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
15. Yaccoby S., Johnson C. L., Mahaffey S. C., Wezeman M. J., Barlogie B. and Epstein J. (2002): Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood, 100, 4162-4168.